Combination of ω-3 fatty acids and cisplatin as a potential alternative strategy for personalized therapy of metastatic melanoma: an in-vitro study
Authors:
- 1 June 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 29 (3) , 270-280
Abstract
The recently developed therapeutic strategies have led to unprecedented improvements in the control of metastatic melanoma and in the survival of specific subgroups of patients. However, drug resistance, low response rates, and undesired side effects make these treatments not suitable or tolerable for all the patients, and chemotherapeutic treatments appear still indispensable, at least for subgroups of patients. New combinatory strategies are also under investigation as tailored treatments or salvage therapies, including combined treatments of immunotherapy with conventional chemotherapy. On this basis, and in consideration of the antineoplastic properties of ω-3 polyunsaturated fatty acids, we have here investigated the potential of these bioactive dietary factors to revert the resistance frequently exhibited by this form of cancer to cisplatin (CDDP, cis-diamminedichloroplatinum). We demonstrated that docosahexenoic acid (DHA, 22:6ω-3) sensitizes the cells to the CDDP-induced inhibition of cell growth and migration by reverting CDDP effects on DNA damage and ERCC1 expression, as well as on the DUSP6 and p-ERK expressions, which regulate ERCC1 activation upwardly. In line, DUSP6 gene silencing prevented the effect of DHA, confirming that DHA acted on the DUSP6/p-ERK/ERCC1 repair pathways to sensitize melanoma cells to the anticancer effect of CDDP. Similar effects were obtained also with eicosapentaenoic acid (20:5ω-3). Overall, our findings suggest that the combination of CDDP treatment with a dietary supplementation with ω-3 polyunsaturated fatty acids could potentially represent a new therapeutic strategy for overcoming CDDP resistance in metastatic melanoma.Keywords
This publication has 45 references indexed in Scilit:
- Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic ChangesPharmacological Reviews, 2012
- Identification of DNA repair gene Ercc1 as a novel target in melanomaPigment Cell & Melanoma Research, 2011
- Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side EffectsCancers, 2011
- Chemopreventive and renal protective effects for docosahexaenoic acid (DHA): implications of CRP and lipid peroxidesCell Division, 2009
- Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cellsCarcinogenesis, 2008
- High expression of DNA repair pathways is associated with metastasis in melanoma patientsOncogene, 2007
- Neuroblastoma cell death in response to docosahexaenoic acid: Sensitization to chemotherapy and arsenic‐induced oxidative stressInternational Journal of Cancer, 2006
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- Influence of Diets Containing Eicosapentaenoic or Docosahexaenoic Acid on Growth and Metastasis of Breast Cancer Cells in Nude MiceJNCI: Journal of the National Cancer Institute, 1995
- Influence of Docosahexaenoic Acid on Cisplatin Resistance in a Human Small Cell Lung Carcinoma Cell LineJNCI: Journal of the National Cancer Institute, 1989